ModifiedUnitedHealthcarePolicy CS129NE.V

Vagus and External Trigeminal Nerve Stimulation (for Nebraska Only)

Policy governing implantable vagus nerve stimulators and nonimplantable vagus and trigeminal nerve stimulation devices for members in the state of Nebraska; defines covered indications (epilepsy) and noncovered/unproven indications.

Policy Summary

PayerUnitedHealthcare

PolicyVagus and External Trigeminal Nerve Stimulation (for Nebraska Only)

Policy CodePolicy CS129NE.V

Change TypeModified — material documentation and evidence updates

Effective DateDecember 1, 2025

Next Review DateN/A

Key ActionProvide complete medical records documenting history, physical examination, and pertinent diagnostic test results to support medical necessity.

SourceLink

POLICY UPDATE CHANGES

Added language specifying required medical record documentation that supports medical necessity for requested services.

Updated Description of Services, Clinical Evidence, and References sections to reflect most current information.

Updated reference link to reflect the current policy title for Transcranial Magnetic Stimulation for Treating Physical Health Conditions (for Nebraska Only).

Removed reference link to the guidelines titled Medical Records Documentation Used for Reviews.

Updated definition of 'Shared Decision Making'.

one statepolicy applicability

≥50% (~42–51%)VNS responder rates

5 trials

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

manyunproven indications

4932025 sham‑controlled TRD trial

03/01/2026most recent revision

Coverage Criteria

Implantable VNS — Medical Necessity (Epilepsy)

Covered when ALL of the following are met:

Implantable VNS for epilepsy coverage criteria: 1) Medically refractory epileptic seizures with failure of two or more trials of single or combination antiepileptic drug therapy or intolerable side effects of antiepileptic drug therapy; AND 2) The individual is not a candidate for epilepsy surgery, has failed epilepsy surgery, or refuses epilepsy surgery after Shared Decision Making discussion; AND 3) No history of left or bilateral cervical vagotomy (contraindication).

FDA identifies prior left or bilateral cervical vagotomy as a contraindication to VNS.

Noninvasive VNS/TNS — Not Medically Necessary

Not medically necessary / Unproven:

Transcutaneous/non-implantable VNS and external TNS: Transcutaneous (non-implantable) vagus nerve stimulation devices and external/transcutaneous trigeminal nerve stimulation devices are considered unproven and not medically necessary for preventing or treating all indications due to insufficient evidence of efficacy.

Examples of conditions listed include ADHD, depression, epilepsy, headache, and others.

Coverage stance by indication

Evidence-supported and investigational indications summarized below; apply AND/OR logic according to indication-specific evidence strength.

Epilepsy (implantable VNS): VNS is an adjunctive treatment option for individuals with drug‑resistant epilepsy when seizures remain uncontrolled after multiple antiseizure medications or when resective surgery is not viable; shared decision‑making is recommended.

Based on Epilepsy Society and NICE guidance.

Treatment‑Resistant Depression (TRD) — implantable VNS: Evidence includes a large 12‑month sham‑controlled trial (n=493) with a non‑significant primary endpoint but positive secondary outcomes, and long‑term registry data (5‑year) showing higher cumulative response and remission rates for adjunctive VNS versus treatment‑as‑usual; overall evidence is limited and further RCTs are needed.

Consider coverage in severe, chronic, highly treatment‑resistant cases when registry‑like criteria and documentation of prior treatment failures are provided.

Cluster Headache — noninvasive VNS (nVNS): Randomized trials show nVNS is superior to sham for episodic cluster headache (eCH) but not for chronic cluster headache (cCH); prophylactic adjunctive nVNS reduced attack frequency in some studies though long‑term and high‑quality evidence are limited.

Coverage evidence groups

Evidence summary-based coverage considerations (not an absolute policy decision):

Supported indications with positive randomized evidence: Episodic cluster headache (nVNS) demonstrated significantly higher response and sustained response rates versus sham in randomized trials; acute episodic migraine showed benefit in some randomized trials and preventive nVNS showed benefit in adherent subsets or certain subgroups in post hoc analyses.

Benefits are most robust for episodic cluster headache and select migraine subgroups; chronic indications have inconsistent or limited data.

Evidence limitations and conditions for coverage: Many trials were limited by small sample sizes, sham devices that produced vagal stimulation, suboptimal adherence, short durations, and other methodological issues; NICE recommends using some transcutaneous procedures only with special arrangements for clinical governance, consent, and audit or research.

These limitations should inform coverage decisions and may prompt requirements for governance or data collection.

Not sufficiently proven/Investigational uses: Transcutaneous vagus or trigeminal stimulation for many other conditions (e.g., epilepsy outside specific contexts, atrial fibrillation, depression, tinnitus, heart failure, impaired glucose tolerance) and eTNS for certain migraine indications lack high‑quality evidence and are considered investigational pending larger trials.

Evidence summaries relevant to coverage

Summary of clinical evidence and guideline positions relevant to coverage determinations

TNS for pediatric ADHD: A blinded sham‑controlled trial (McGough et al. 2019) showed statistically significant improvements for active TNS versus sham on ADHD scales, but only slightly more than half achieved clinically meaningful improvement; the AAP states eTNS cannot be recommended due to sparse evidence compared with established therapies.

Durability and developmental impact require further study.

e‑TNS for acute migraine: A randomized double‑blind sham‑controlled trial (Chou et al. 2019) using the Cefaly device found significant reduction in pain intensity at 1 hour for verum versus sham, with good tolerability; NICE advises that acute use should be within special arrangements for governance/consent/audit or research.

Evidence for prevention is inadequate in quality and quantity per NICE.

TNS for major depressive disorder: A small randomized phase II trial (Generoso et al. 2019; n=24) reported reductions in HDRS‑17 scores with active TNS and sustained effect at 1 month, but limitations include small sample size and short follow‑up; long‑term efficacy remains uncertain.

Implantable vagus nerve stimulation (VNS) is considered not medically necessary for indications other than medically refractory epilepsy. The policy lists multiple non‑epilepsy conditions for which implantable VNS is unproven and excluded from coverage, including but not limited to Alzheimer’s disease, anxiety, autism spectrum disorder, depression, migraine, cluster headaches, fibromyalgia, heart failure, morbid obesity, sleep disorders, and obsessive-compulsive disorder. Transcutaneous (non‑implantable) VNS and external/transcutaneous trigeminal nerve stimulation devices are also considered unproven and not medically necessary for preventing or treating all indications due to insufficient evidence of efficacy.

Vagus nerve stimulation—whether implantable or transcutaneous—is investigational for a wide range of conditions beyond refractory epilepsy. The evidence base is limited by small studies and weak designs; examples of investigational indications include Alzheimer’s disease, autism spectrum disorder, obsessive‑compulsive disorder, chronic pain, sleep disorders, heart failure, asthma, and various psychiatric and neurologic disorders. Larger, higher‑quality clinical trials are required before coverage can be considered for these uses.

Transcutaneous (non‑implantable) vagus nerve stimulation (tVNS) has been evaluated for multiple conditions (e.g., atrial fibrillation, epilepsy, depression, heart failure, impaired glucose tolerance, tinnitus, sleep quality), but current studies are limited by small sample sizes and heterogeneous designs. As a result, tVNS is considered investigational and not medically necessary for these other indications until robust evidence from larger trials establishes safety and efficacy.

The American Academy of Pediatrics reviewed pediatric data on external trigeminal nerve stimulation (eTNS) and concluded that eTNS cannot be recommended as a treatment for attention‑deficit/hyperactivity disorder (ADHD). The guideline cites sparse supporting evidence that does not approach the strength of established medication and behavioral therapies.

This Medical Policy is intended to assist in interpreting UnitedHealthcare standard benefit plans; however, federal, state, or contractual requirements govern in the event of conflict. UnitedHealthcare may use third‑party tools (for example, InterQual®) to assist in benefit administration. The policy is informational and does not substitute for the independent clinical judgment of treating providers.

Use of implantable VNS for many non‑epilepsy indications (for example, Alzheimer’s disease, depression, migraine, cluster headache, obesity, post‑traumatic stress disorder, and numerous other neurologic, psychiatric, cardiac, autoimmune, and musculoskeletal conditions) is considered unproven and not medically necessary because available studies are limited, heterogeneous, and insufficient to demonstrate clinically meaningful benefit.

Overall, transcutaneous vagus nerve stimulation lacks sufficient high‑quality evidence to support routine clinical use across most indications. Systematic reviews and device‑specific assessments note study limitations, inconsistent outcomes, and the need for larger randomized controlled trials; therefore tVNS is considered insufficiently evidenced and not medically necessary outside of well‑supported uses.

External or transcutaneous trigeminal nerve stimulation (eTNS/TNS) has shown some positive findings in migraine and other small studies, but the overall evidence quality is low and heterogeneous. Systematic reviews and evidence assessments conclude there is insufficient robust evidence to support routine coverage for most indications, and further high‑quality comparative studies are needed to define efficacy, optimal protocols, and long‑term outcomes.

For drug‑resistant epilepsy, existing systematic reviews (e.g., Boon et al. 2018) and subsequent evaluations conclude that evidence is currently insufficient to support the efficacy of trigeminal nerve stimulation (TNS). While small studies report reduction in seizure frequency and acceptable tolerability, methodological limitations and heterogeneity prevent definitive conclusions and routine coverage.

Coding and Codes

Covered CPT Codes (reference)CPT

61885	Insertion or replacement of cranial neurostimulator pulse generator or receiver; with connection to a single electrode array.
61886	Insertion or replacement of cranial neurostimulator pulse generator or receiver; with connection to 2 or more electrode arrays.
64553	Percutaneous implantation of neurostimulator electrode array; cranial nerve.
64568	Open implantation of cranial nerve (e.g., vagus nerve) neurostimulator electrode array and pulse generator.
64570	Removal of cranial nerve (e.g., vagus nerve) neurostimulator electrode array and pulse generator.

Covered HCPCS Codes (reference)HCPCS

A4541	Monthly supplies for use of device coded at E0733.
E0733	Transcutaneous electrical nerve stimulator for electrical stimulation of the trigeminal nerve.
E0735	Noninvasive vagus nerve stimulator.
E0770	Functional electrical stimulator, transcutaneous stimulation of nerve and/or muscle groups, any type, complete system, not otherwise specified.
E1399	Durable medical equipment, miscellaneous.
L8679	Implantable neurostimulator, pulse generator, any type.
L8680	Implantable neurostimulator electrode, each.

Additional HCPCS / Implantable Device CodesHCPCS

L8682	Implantable neurostimulator radiofrequency receiver.
L8683	Radiofrequency transmitter (external) for use with implantable neurostimulator radiofrequency receiver.
L8685	Implantable neurostimulator pulse generator, single array, rechargeable, includes extension.
L8686	Implantable neurostimulator pulse generator, single array, nonrechargeable, includes extension.
L8687	Implantable neurostimulator pulse generator, dual array, rechargeable, includes extension.
L8688	Implantable neurostimulator pulse generator, dual array, nonrechargeable, includes extension.

Implantable VNS device product codesmixed

LYJ	FDA product code referenced for implantable vagus nerve stimulators (PMA listings)
MUZ	FDA product code referenced for implantable vagus nerve stimulators (PMA listings)
QPY	FDA product code referenced for implantable vagus nerve stimulators (PMA listings)

Transcutaneous VNS device product codesmixed

PKR	FDA product code referenced for transcutaneous (non-implantable) vagus nerve stimulation devices (PMN listings)
QAK	FDA product code referenced for transcutaneous (non-implantable) vagus nerve stimulation devices (PMN listings)

External/trigeminal nerve stimulation device product codesmixed

PCC	FDA product code referenced for external/transcutaneous trigeminal nerve stimulation devices (PMN listings)
QGL	FDA product code referenced for external/transcutaneous trigeminal nerve stimulation devices (PMN listings)

Adherence thresholds used in trials

PREMIUM post-hoc adherence threshold≥67% adherence per month (post-hoc subgroup analysis showed significant benefit in adherent participants)

PREMIUM II modified ITT adherence requirementCompletion of ≥70 days of the double-blind period AND ≥66% adherence (prespecified modified ITT population)

Run-in period used for baseline diary4-week headache/migraine diary run-in to establish baseline prior to randomization (used in trials assessing adherence/evaluable populations)

Primary response timepoint for cluster headache trial

Primary response timepoint

Provider Actions and Documentation

Prior Authorization

Prior authorization and related expectations

Prior authorization may be required for services billed with the procedure and supply codes listed in this policy. Requests for implantable VNS for epilepsy or treatment‑resistant depression (TRD) should include documentation of prior medication trials and other coverage criteria (see medical necessity criteria). UnitedHealthcare may apply federal, state, or contractual requirements when determining benefit coverage.

Prior authorization expectations: include device model, manufacturer, and FDA marketing clearance/PMA information; clinical records documenting prior antiseizure or antidepressant therapy trials; shared decision‑making documentation when surgery is declined or not an option.
Prior authorization implied for services billed with listed procedure and supply codes.

Documentation Required

Device identification and FDA clearance documentation

For implantable devices, documentation must identify the device model and include FDA marketing clearance or Premarket Approval (PMA) details (product codes LYJ, MUZ, QPY referenced). For non‑implantable/transcutaneous devices, provide 510(k) or PMN/clearance information (product codes PKR, QAK for tVNS; PCC, QGL for trigeminal stimulators).

Background

Vagus nerve stimulation delivers electrical impulses to the brain via the vagus nerve. Implantable systems use an implanted pulse generator and cervical leads and are an established adjunctive treatment for medically refractory epilepsy when specific criteria are met. Noninvasive approaches include transcutaneous vagus nerve stimulation (tVNS) and external/transcutaneous trigeminal nerve stimulation (eTNS/TNS), which apply stimulation via external devices and are under active study for headache, mood, epilepsy, and other indications. Evidence quality and indication‑specific results vary substantially between implanted and non‑implantable modalities.

Definitions

Shared Decision Making — definition

DefinitionShared Decision Making is a collaborative process in which a provider and patient (including caregivers) work together to make healthcare decisions, weighing evidence, clinician experience, and the patient’s values and preferences

Key elementsComparison of benefits, harms, and risks of options; discussion of what matters most to the patient

Source guidanceAHRQ description used as reference (About Shared Decision Making, 2023); policy updated definition noted in revision history

AAN Level C — definition

AAN Level C meaningDefined as possibly effective, ineffective, or harmful (or possibly useful/predictive or not useful/predictive) for the specified condition and population

Evidence requirement

Revision History

2026-03-01updated_referenceLatest

Updated reference link to reflect the current policy title for Transcranial Magnetic Stimulation for Treating Physical Health Conditions (for Nebraska only).

2025-12-01added_documentation_requirement

Added language requiring that the patient medical record contain documentation that fully supports medical necessity, including relevant history, physical exam, and results of pertinent diagnostic tests or procedures, and that documentation be legible and available upon request.

2025-12-01content_update

Policy Summary

PayerUnitedHealthcare

PolicyVagus and External Trigeminal Nerve Stimulation (for Nebraska Only)

Policy CodePolicy CS129NE.V

Change TypeModified — material documentation and evidence updates

Effective DateDecember 1, 2025

Next Review DateN/A

Key ActionProvide complete medical records documenting history, physical examination, and pertinent diagnostic test results to support medical necessity.

SourceLink

On This Page

nVNS may be considered for eCH based on RCTs; evidence for cCH is insufficient.

Transcutaneous (non‑implantable) VNS for other indications: Insufficient evidence to support use of transcutaneous VNS for indications beyond episodic cluster headache; larger, higher‑quality studies are needed to establish safety, efficacy, and long‑term outcomes.

Includes investigational uses such as Alzheimer’s, autism, anxiety, OCD, chronic pain, heart failure, and others.

Systematic reviews call for larger, higher‑quality randomized trials.

Insufficient long‑term evidence for routine coverage.

TNS for drug‑resistant epilepsy: Systematic reviews (e.g., Boon et al. 2018) and subsequent assessments conclude there is insufficient data to support efficacy of TNS for drug‑resistant epilepsy.

Further data collection is warranted before considering coverage.

Pain relief (pain intensity 0 or 1) at 15 minutes after treatment initiation for the first cluster headache attack, without rescue medication use through 60 minutes

Sustained response windowSustained response evaluated 15–60 minutes after treatment initiation

Population and design noteDouble-blind randomized trial with 150 enrolled subjects; prespecified analyses for episodic and chronic cluster headache cohorts

Include searchable identifiers (manufacturer, model, and FDA 510(k) or PMA number) in authorization requests.
If device clearance cannot be documented, the request may be delayed or denied.

Note

Coverage determination and use of tools

Coverage decisions are made in the context of applicable federal, state, and contractual benefit terms. UnitedHealthcare may use third‑party clinical tools (for example, InterQual®) to assist in determining medical necessity. Inclusion of codes in this policy is for reference and does not guarantee coverage.

Benefit coverage is governed by plan terms; in case of conflict, federal/state/contractual requirements prevail.
Third‑party criteria may be applied to support adjudication.

Denial Risk

Contraindication — prior cervical vagotomy

A history of left or bilateral cervical vagotomy is a contraindication to vagus nerve stimulation per FDA guidance. Requests for VNS in members with prior cervical vagotomy should be denied unless clear supporting documentation demonstrates absence of contralateral or left vagotomy.

Document surgical history clearly; absence of documentation increases denial risk.

Denial Risk

Use of transcutaneous (non‑implantable) VNS

Transcutaneous (non‑implantable) VNS and other non‑implant neuromodulation modalities have limited and mixed evidence. The policy finds insufficient evidence to support many non‑implantable VNS indications; such requests may be denied or considered investigational unless criteria and supporting evidence meet plan requirements.

Non‑implantable/transcutaneous VNS: provide clinical rationale, peer‑reviewed evidence, and device clearance info. Lack of robust evidence may trigger coverage denial.
NICE and other guidance note limited efficacy and recommend special arrangements for some transcutaneous applications.

Note

NICE governance and special‑arrangement recommendations

NICE recommends that implanted VNS for treatment‑resistant depression and certain transcutaneous stimulation procedures for migraine/cluster headache be used only with special arrangements for clinical governance, consent, and audit or research. Where applicable, document that these governance arrangements, consent discussions, and plans for audit or data collection have occurred.

Document informed consent and that the procedure is performed under governance/audit/research protocols when relying on evidence limited in quality or quantity.
Where NICE recommends special arrangements for acute migraine supraorbital stimulation, include governance and consent documentation in the record.

Denial Risk

Documentation requirements and denial risk for incomplete records

Failure to provide required medical records and supporting documentation may result in denial of the request. The patient record must fully support medical necessity and be legible and available upon request.

Required documentation includes relevant medical history, physical exam, diagnostic test results, device model and clearance data, prior treatment trial records, and shared decision‑making notes.
Failure to submit these documents may lead to case denial or processing delays.

Documentation Required

Baseline headache diary and adherence documentation

Clinical trials and guidance emphasize the importance of baseline headache diaries and adherence monitoring in studies of noninvasive VNS for migraine. Authorization for preventive or acute neuromodulation for headache should include baseline headache diary data and evidence of treatment adherence where applicable.

Provide a 4‑week baseline headache diary or equivalent documentation of baseline headache burden when requesting coverage for migraine neuromodulation.
Document adherence monitoring (for example, ≥67% adherence thresholds used in trials) when relying on efficacy data tied to adherence.

Prior Authorization

Medication failure and clinical indications for implantable VNS

For implantable VNS in epilepsy, documentation must show failure of two or more antiepileptic drug trials (single or combination) or intolerable side effects. VNS is considered when seizures remain uncontrolled after multiple antiseizure medications and when resective surgery is not viable, has failed, or is refused following shared decision‑making.

Include detailed medication trial history (agents, doses, durations, reason for discontinuation) to demonstrate medication failure.
Document shared decision‑making and rationale if surgery is not pursued.

Documentation Required

Consideration of prior pharmacologic therapy documentation

Consider documenting trials of pharmacologic therapies before neuromodulation for migraine and depression where clinical guidelines recommend pharmacologic first‑line approaches. For acute nVNS in migraine, AHS notes FDA clearance for acute use and suggests nVNS as an option for individuals who have failed, cannot tolerate, or prefer nondrug therapies; include pharmacologic trial details when relevant.

When applicable, include documentation of failed or contraindicated pharmacologic therapies (names, durations, outcomes) for the indication being treated.
Absence of prior pharmacologic trial documentation may affect medical necessity determinations.

Step Therapy

Step therapy — verify plan requirements

No explicit step‑therapy requirements are specified in this section; however, plan terms and applicable benefit rules may impose step therapy. Verify the member's plan documents and federal/state/contractual requirements for any step‑therapy obligations before authorization.

UnitedHealthcare policy does not add plan‑level step therapy here; check the member's benefit plan for any required step‑therapy protocols.
In cases where step therapy applies, include evidence of completion or exemption in the authorization request.

Requires at least one Class II study or two consistent Class III studies to assign Level C

ImplicationIndicates limited/conflicting evidence; cautious interpretation for coverage decisions

nVNS (noninvasive vagus nerve stimulation) — definition

DefinitionNoninvasive vagus nerve stimulation (nVNS) refers to transcutaneous or external stimulation of the cervical vagus nerve (e.g., gammaCore) used for acute and preventive treatment of cluster headache and migraine

Typical protocolsDevices often deliver brief stimulations bilaterally to the neck (e.g., two 120-second stimulations, three times daily for prevention) or within minutes of attack onset for acute treatment

Clinical trial contextStudied in randomized sham-controlled trials showing efficacy for episodic cluster headache and mixed results for migraine prevention, with adherence and sham device activity affecting outcomes

eTNS / TNS (external/transcutaneous trigeminal nerve stimulation) — definition

DefinitionExternal/transcutaneous trigeminal nerve stimulation (eTNS/TNS) is external stimulation applied to the trigeminal (supraorbital) nerve (e.g., Cefaly device) for acute or preventive migraine treatment

Evidence summarySystematic reviews and randomized trials report reductions in migraine frequency and acute pain versus sham, but overall quality of evidence is low and long-term durability is uncertain

Clinical useStudied for episodic and chronic migraine and investigated in other conditions (ADHD, depression, epilepsy), with device-specific protocols for acute (1-hour) or nightly preventive use

External/transcutaneous trigeminal nerve stimulation (TNS/eTNS) — definition

DefinitionExternal/transcutaneous trigeminal nerve stimulation (TNS/eTNS) denotes noninvasive neurostimulation applied to the trigeminal (supraorbital) nerve using external devices (e.g., Cefaly) for migraine and investigational uses

Key trial findingsTrials show acute and preventive benefit in some randomized studies (e.g., reduced pain intensity at 1 hour; modest reductions in migraine days), but evidence quality and consistency are limited

Evidence limitationsUncertainty about optimal protocols, long-term durability, and generalizability; higher-quality trials needed

Transcutaneous vagus nerve stimulation (tVNS; non-implantable) — definition

DefinitionTranscutaneous vagus nerve stimulation (tVNS) is noninvasive stimulation of auricular or cervical branches of the vagus nerve using external devices distinct from implantable VNS systems

Regulatory statusFDA-listed transcutaneous VNS devices referenced via product codes PKR and QAK (device listings on FDA PMN/PMN pages)

Clinical distinctionUsed in trials for migraine and cluster headache and differs from implantable VNS in device type, invasiveness, and approved indications

Shared Decision Making

Definition (concise)Shared Decision Making is a collaborative process between provider and patient that weighs evidence, clinician experience, and patient values and preferences when choosing treatments

Documentation recommendationShared decision-making discussion and documentation of benefits/risks is recommended prior to proceeding with VNS (NICE and policy guidance)

Policy notePolicy definition was updated in the recent revision history (see Policy History)

Updated Description of Services, Clinical Evidence, and References sections to reflect the most current information and archived previous policy version CS129.U.